Eli Lilly And Co (NYSE:LLY) major shareholder Eli & Co Lilly sold 10,059 shares of the stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $14.83, for a total value of $149,174.97. Following the completion of the sale, the insider now directly owns 3,894,318 shares of the company’s stock, valued at $57,752,735.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Eli & Co Lilly also recently made the following trade(s):

  • On Monday, September 17th, Eli & Co Lilly sold 6,865 shares of Eli Lilly And Co stock. The shares were sold at an average price of $14.58, for a total value of $100,091.70.
  • On Friday, September 14th, Eli & Co Lilly sold 9,009 shares of Eli Lilly And Co stock. The shares were sold at an average price of $14.58, for a total value of $131,351.22.
  • On Monday, September 10th, Eli & Co Lilly sold 4,500 shares of Eli Lilly And Co stock. The stock was sold at an average price of $14.44, for a total value of $64,980.00.
  • On Monday, August 13th, Eli & Co Lilly sold 4,531 shares of Eli Lilly And Co stock. The stock was sold at an average price of $14.33, for a total value of $64,929.23.

LLY opened at $115.02 on Friday. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $115.68. The firm has a market cap of $115.25 billion, a P/E ratio of 26.87, a P/E/G ratio of 1.88 and a beta of 0.29.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The firm had revenue of $6.36 billion for the quarter, compared to analyst estimates of $6.05 billion. During the same period last year, the company earned $1.11 EPS. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. Equities analysts predict that Eli Lilly And Co will post 5.47 earnings per share for the current fiscal year.

LLY has been the subject of several analyst reports. TheStreet cut Eli Lilly And Co from a “b” rating to a “c+” rating in a research note on Friday, August 24th. Morgan Stanley increased their price objective on Eli Lilly And Co from $93.00 to $102.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 31st. Berenberg Bank cut Eli Lilly And Co from a “buy” rating to a “hold” rating and set a $99.00 price objective for the company. in a research report on Wednesday, July 25th. They noted that the move was a valuation call. Goldman Sachs Group set a $100.00 price objective on Eli Lilly And Co and gave the stock a “neutral” rating in a research report on Wednesday, July 25th. Finally, SunTrust Banks upped their target price on Eli Lilly And Co from $105.00 to $123.00 and gave the company a “buy” rating in a report on Monday, October 1st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $106.06.

Large investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC purchased a new position in shares of Eli Lilly And Co in the 2nd quarter worth about $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of Eli Lilly And Co in the 2nd quarter worth about $114,000. Legacy Advisors LLC raised its holdings in shares of Eli Lilly And Co by 118.0% in the 2nd quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after purchasing an additional 733 shares during the period. Fort L.P. purchased a new position in shares of Eli Lilly And Co in the 2nd quarter worth about $121,000. Finally, Financial Management Professionals Inc. purchased a new position in shares of Eli Lilly And Co in the 2nd quarter worth about $128,000. 76.56% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Why is insider trading harmful?

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.